Aurobindo Pharma growth revival driven by Europe, biosimilars and Lannett synergies

Investment View and Valuation

In its August 6, 2026 result update, ICICI Direct Research maintained its BUY recommendation on Aurobindo Pharma, with a target price of Rs 1,970 against a CMP of Rs 1,595. The target price is based on 18 times FY28E EPS of Rs 109.4.

The broker views Aurobindo Pharma as an export-driven global producer of generic formulations and APIs with substantial US and European exposure. Its position is supported by vertical integration and diversification into injectables, oncology oral solids, biosimilars and biologics. ICICI Direct believes the company has a considered de-risking strategy through reduced dependence on US generics.

Q1 FY27 Financial Performance

Aurobindo Pharma reported a strong Q1 FY27, marking a return to growth after a difficult FY26. ICICI Direct described the quarterly performance as broadly in line with expectations.

The improvement in gross profit margin was aided mainly by internal Pen G consumption. Operating income also increased 3.4% quarter on quarter.

Segment Performance

Europe was the key growth contributor in Q1 FY27, while all major businesses other than ARV recorded growth.

Management Guidance and Growth Outlook

Management reiterated guidance for double-digit FY27 revenue growth, an EBITDA margin above 21% and absolute EBITDA above Rs 8,000 crore. High-value strategic businesses could provide additional upside.

• Europe is expected to deliver double-digit FY27 growth at around 20% EBITDA margin.
• Eugia is guided to grow at a single-digit rate and generate about US dollar 500 million of FY27 revenue.
• During Q1 FY27, the company launched 10 products in the US, filed nine ANDAs and received 10 final approvals.

Lannett Acquisition and Synergies

The Lannett acquisition is expected to improve margins through selling, general and administrative cost rationalisation, operating leverage and procurement synergies. Some benefits are anticipated within nine months.

• Lannett's Advair product was scheduled for launch in August.
• Development of Spiriva and Flovent continues.
• Management intends to use Lannett's 40% unutilised capacity by transferring products, including government-business products.
• Capacity utilisation is targeted to reach a reasonable level within 12 months.

Biosimilars, Biologics and Contract Manufacturing

Biosimilars, biologics and contract manufacturing are additional longer-term growth drivers. Management expects two to three US biosimilar filings during FY27 and targets at least three products by 2030.

• The Omalizumab filing with the European Medicines Agency is on track for Q3.
• Denosumab has been filed with CHMP or EMA.
• TheraNyM CMO Unit 1 is expected to begin revenue generation in 2028 and Unit 2 in 2031.
• Combined TheraNyM CMO revenue is targeted at US dollar 150 million to US dollar 200 million from 2032, with EBITDA margins of 35% to 50%.
• Pen G production is currently 800 to 900 tonnes.

Financial Estimates

Key Monitorables and Risks

Key monitorables

• EBITDA-margin improvement amid higher R&D and expansion into complex products.
• Resolution of Eugia III issues following fresh observations.
• Lannett consolidation and the realisation of planned synergies.
• Launch momentum across markets.

Key risks

• Slower-than-expected US new-product ramp-up.
• Unforeseen expenses arising from recurring regulatory issues.